Reasons Behind Adma Biologics (ADMA) Decline Exceeding Market Trends
Stock Performance: Adma Biologics (ADMA) closed at $14.56, down 3.51%, underperforming compared to the S&P 500 and other indices, with a 3.02% decline over the past month.
Earnings Projections: The upcoming earnings report is expected to show a 6.67% increase in EPS to $0.16 and an 8.56% rise in revenue to $130.1 million, with annual forecasts indicating significant growth in both earnings and revenue.
Analyst Sentiment: Changes in analyst estimates are crucial for understanding business trends, with Adma Biologics currently holding a Zacks Rank of #3 (Hold), indicating stable expectations.
Valuation Insights: Adma Biologics has a Forward P/E ratio of 26.47, higher than the industry average, and operates within a strong industry rank, suggesting potential for future performance.
Trade with 70% Backtested Accuracy
Analyst Views on ADMA
About ADMA
About the author
Ranger Investment Management Increases Solaris Holdings
- Share Increase: On February 13, 2026, Ranger Investment Management disclosed an increase of 197,073 shares in Solaris Energy Infrastructure, representing an estimated $9.53 million trade, indicating strong confidence in the company.
- Market Value Growth: The quarter-end value of Solaris increased by $11.62 million due to both the share addition and stock price movement, reflecting robust performance and market recognition in the energy infrastructure sector.
- Financial Performance: Solaris reported $167 million in third-quarter revenue, a 12% sequential increase, with net income of $25 million, showcasing strong growth potential in energy infrastructure tied to electrification and data centers.
- Future Outlook: Management raised fourth-quarter Adjusted EBITDA guidance to $65 million to $70 million and initiated first-quarter 2026 guidance, demonstrating confidence in future growth and an aggressive capital expenditure plan.
Ranger Investment Management Increases Solaris Shares
- Share Increase: Ranger Investment Management acquired 197,073 shares of Solaris in Q4 2026, with an estimated trade value of $9.53 million, reflecting the firm's confidence in Solaris's growth potential.
- Position Value Growth: The quarter-end value of Solaris's position rose by $11.62 million, indicating not only an increase in shares but also a positive impact from stock price appreciation, further solidifying Ranger's investment strategy.
- Strong Financial Performance: Solaris reported $167 million in revenue for Q3, a 12% sequential increase, with a net income of $25 million, showcasing its robust performance and growth potential in the energy infrastructure market.
- Optimistic Future Outlook: Management raised fourth-quarter Adjusted EBITDA guidance to $65 million to $70 million and initiated first-quarter 2026 guidance of $70 million to $75 million, indicating strong confidence in future performance.
ADMA Biologics CEO to Present at J.P. Morgan Healthcare Conference
- Conference Participation: ADMA Biologics CEO Adam Grossman will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 AM PT, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor interest.
- Product Portfolio: ADMA currently markets three FDA-approved plasma-derived biologics for treating immune deficiencies and preventing certain infectious diseases, highlighting the company's market positioning and expertise in niche medical areas.
- R&D Initiatives: ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, indicating the company's ongoing commitment to innovative drug development aimed at meeting the needs of specific patient populations.
- Manufacturing Capabilities: ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, ensuring the quality and stability of its biologics supply, thereby reinforcing its competitive advantage in the biopharmaceutical market.
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.
Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.
Wall Street Analysts Predict a 60.24% Surge for Adma Biologics (ADMA): Important Insights Before You Invest
Stock Performance: Adma Biologics (ADMA) shares have risen 23.3% recently, closing at $19.14, with Wall Street analysts projecting a mean price target of $30.67, suggesting a potential upside of 60.2%.
Analyst Price Targets: While the consensus price target shows strong agreement among analysts, there are concerns about the reliability of these targets, as they may be influenced by business relationships and could mislead investors.
Earnings Estimates: Analysts have revised ADMA's earnings estimates upward, indicating optimism about the company's performance, which historically correlates with positive stock price movements.
Investment Caution: Investors are advised to approach price targets with skepticism and consider them as one of many factors in their investment decisions, rather than relying solely on them for potential returns.
Ranger Investment Management Increases Solaris Holdings
- Share Increase: On February 13, 2026, Ranger Investment Management disclosed an increase of 197,073 shares in Solaris Energy Infrastructure, representing an estimated $9.53 million trade, indicating strong confidence in the company.
- Market Value Growth: The quarter-end value of Solaris increased by $11.62 million due to both the share addition and stock price movement, reflecting robust performance and market recognition in the energy infrastructure sector.
- Financial Performance: Solaris reported $167 million in third-quarter revenue, a 12% sequential increase, with net income of $25 million, showcasing strong growth potential in energy infrastructure tied to electrification and data centers.
- Future Outlook: Management raised fourth-quarter Adjusted EBITDA guidance to $65 million to $70 million and initiated first-quarter 2026 guidance, demonstrating confidence in future growth and an aggressive capital expenditure plan.
Ranger Investment Management Increases Solaris Shares
- Share Increase: Ranger Investment Management acquired 197,073 shares of Solaris in Q4 2026, with an estimated trade value of $9.53 million, reflecting the firm's confidence in Solaris's growth potential.
- Position Value Growth: The quarter-end value of Solaris's position rose by $11.62 million, indicating not only an increase in shares but also a positive impact from stock price appreciation, further solidifying Ranger's investment strategy.
- Strong Financial Performance: Solaris reported $167 million in revenue for Q3, a 12% sequential increase, with a net income of $25 million, showcasing its robust performance and growth potential in the energy infrastructure market.
- Optimistic Future Outlook: Management raised fourth-quarter Adjusted EBITDA guidance to $65 million to $70 million and initiated first-quarter 2026 guidance of $70 million to $75 million, indicating strong confidence in future performance.
ADMA Biologics CEO to Present at J.P. Morgan Healthcare Conference
- Conference Participation: ADMA Biologics CEO Adam Grossman will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 AM PT, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor interest.
- Product Portfolio: ADMA currently markets three FDA-approved plasma-derived biologics for treating immune deficiencies and preventing certain infectious diseases, highlighting the company's market positioning and expertise in niche medical areas.
- R&D Initiatives: ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, indicating the company's ongoing commitment to innovative drug development aimed at meeting the needs of specific patient populations.
- Manufacturing Capabilities: ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, ensuring the quality and stability of its biologics supply, thereby reinforcing its competitive advantage in the biopharmaceutical market.
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.
Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.
Wall Street Analysts Predict a 60.24% Surge for Adma Biologics (ADMA): Important Insights Before You Invest
Stock Performance: Adma Biologics (ADMA) shares have risen 23.3% recently, closing at $19.14, with Wall Street analysts projecting a mean price target of $30.67, suggesting a potential upside of 60.2%.
Analyst Price Targets: While the consensus price target shows strong agreement among analysts, there are concerns about the reliability of these targets, as they may be influenced by business relationships and could mislead investors.
Earnings Estimates: Analysts have revised ADMA's earnings estimates upward, indicating optimism about the company's performance, which historically correlates with positive stock price movements.
Investment Caution: Investors are advised to approach price targets with skepticism and consider them as one of many factors in their investment decisions, rather than relying solely on them for potential returns.
